U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) – 2020 to 2025

$3,850.00$5,850.00

AVAIL 20% DISCOUNT ON PURCHASE OF ANY REPORT
Published on: April 9, 2020
Clear
SKU: GMS-3200 Category:

The U.S. insomnia treatment market is expected to cross USD 5.43 billion by 2025, rising from 2020 to 2025 at a CAGR of 3.87%. This rise can be due to the advent of new medications to treat insomnia and government funding to reduce the increasing cost of insomnia. Nonetheless, due to the decline in the sales of branded drugs and the may acceptance of generics due to their low cost and equivalent effectiveness as opposed to branded products, market growth could be hampered.

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 1

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 2

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 3

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 4

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 5

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 6

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 7

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2020 to 2025 8

1 U.S. Insomnia Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 U.S. Insomnia Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 U.S. Insomnia Market – Industry Market Entry Scenario
4.1 Regulatory Framework Overview
4.2 New Business and Ease of Doing business index
4.3 Case studies of successful ventures
4.4 Customer Analysis – Top 10 companies

5 U.S. Insomnia Market – Market Forces
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Opportunities
5.2.3 Challenges
5.3 Porters Analysis of Market
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining powers of customers
5.3.3 Threat of new entrants
5.3.4 Rivalry among existing players
5.3.5 Threat of substitutes

6 U.S. Insomnia Market – Strategic Analysis
6.1 Value Chain analysis
6.2 Supplier and distributor analysis (Market share and product dealing strategies)

7 U.S. Insomnia Market – By Treatment (Market Size – & million/billion)
7.1 Pharmacological Treatments
7.2 Non-pharmacological Treatments

8 U.S. Insomnia Market – By Pharmacological Treatment
8.1 Prescription Sleep Aids
8.2 Over-the-Counter Sleep Aids

9 U.S. Insomnia Market – By Non-pharmacological Treatment
9.1 Cognitive Behavioral Therapy for Insomnia (CBTI)
9.2 Hypnotherapy
9.3 Other

10 U.S. Insomnia Market – Entropy
10.1 New product launches
10.2 M&A’s, collaborations, JVs and partnerships

11 U.S. Insomnia Market Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Merck & Co., Inc.
11.3 Eisai Co., Ltd.
11.4 Meda Consumer Healthcare, Inc
11.5 Takeda Pharmaceuticals Company Ltd.
11.6 Purdue Pharmaceuticals L.P.
11.7 Sanofi
11.8 Vanda Pharmaceuticals
11.9 Pernix Therapeutics
11.10 Pfizer Inc.
11.11 Company 10
11.12 Company 11 & more

12 U.S. Insomnia Market – Appendix
12.1 Sources
12.2 Abbreviations